Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
Richard M. Stone(Dana-Farber Cancer Institute), Hartmut Döhner(University Hospital Ulm), Sumithra J. Mandrekar(Mayo Clinic), Andrew H. Wei(The Royal Melbourne Hospital), Christian Thiede(University Hospital Carl Gustav Carus), Susan M. Geyer(Mayo Clinic in Florida), Arnold Ganser(Medizinische Hochschule Hannover), Gerhard Ehninger(University Hospital Carl Gustav Carus), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Jorge Sierra(Universitat Autònoma de Barcelona), Rebecca B. Klisovic(Goethe University Frankfurt), Joseph Brandwein(Goethe University Frankfurt), Dietger Niederwieser(Leipzig University of Applied Sciences), Richard F. Schlenk(German Cancer Research Center), Konstanze Döhner(University Hospital Ulm), Ben L. Sanford(Duke University), Kristina Laumann(Goethe University Frankfurt), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Guido Marcucci(City of Hope), Clara D. Bloomfield(North Shore University Hospital), Francesco Lo‐Coco(Fondazione Santa Lucia), Richard A. Larson(Urbana University), Sergio Amadori(Polyclinic Medical Center), Hubert Serve(Goethe University Frankfurt), Théo de Witte(Radboud University Nijmegen), Jürgen Krauter(Klinikum Braunschweig), Bruno C. Medeiros(Stanford Medicine), Thomas W. Prior(Goethe University Frankfurt), Martin S. Tallman(Memorial Sloan Kettering Cancer Center)
Cited by 2,191
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k